PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells

Xiao-Fen Lai††, Cong-Xiang Shen††, Zhong Wen†‡*, Yu-Hong Qian†, Chao-Sheng Yu†, Jun-Qi Wang†, Ping-Neng Zhong† and Hai-Li Wang†

Abstract

Background: Human interacting protein X1 (PinX1) has been identified as a critical telomerase inhibitor and proposed to be a putative tumor suppressor gene. Loss of PinX1 has been found in a large variety of malignancies, however, its function in inhibiting telomerase activity of tumor cells is not well documented. Here we show that PinX1 is essential for down-regulation telomerase activity of nasopharyngeal carcinoma.

Methods: Expression vectors of human PinX1 (pEGFP-C3-PinX1) and its small interfering RNA (PinX1-FAM-siRNA) were constructed and transfected into NPC. Their effects on mRNA of telomerase catalytic subunit (hTERT), telomerase activity, cell proliferation, cell migration, wound healing, cell cycles and apoptosis were examined using semi-quantitative RT-PCR, stretch PCR, MTT assay, Transwell, scratch assay and flow cytometry, respectively.

Results: Transfection of pEGFP-C3-PinX1 and PinX1-FAM-siRNA increased and reduced PinX1 mRNA by 1.6-fold and 70%, respectively. Over-expression of PinX1 decreased hTERT mRNA by 21%, reduced telomerase activity, inhibited cell growth, migration and wound healing ability, arrested cells in G0/G1 phase, and increased apoptotic index. In contrast, down-regulation of PinX1 did not alter the above characteristics.

Conclusions: PinX1 may play important roles in NPC proliferation, migration and apoptosis and has application potential in tumor-targeted gene therapy.

Keywords: PinX1, Telomerase inhibitor, Proliferation, Migration, Apoptosis, Cell cycle, Human nasopharyngeal carcinoma

Background

Nasopharyngeal carcinoma (NPC) is one of the most incident and dangerous malignant tumors in southern provinces of China. Genetic factors and environmental factors including Epstein-Barr virus are the two major risk factors for NPC. Radiotherapy along with other auxiliary methods such as chemotherapy is used to treat NPC. Although equipments and technologies in radiotherapy and chemotherapy have been greatly advanced in recent years, the 5-year survival rate of patients with NPC remains about 70%. In addition, systemic and local side effects caused by chemotherapy greatly humbled the patient physically and psychologically. Therefore, it is of importance to study the etiology of NPC and explore new, safe and effective modalities for NPC therapy.

Telomerase is well known for its role in the development of malignant tumors. Studies from our group and others [1,2] have found enhanced mRNA level of telomerase catalytic subunit (TERT) and telomerase expression in 88% of NPC specimens and NPC cell line HNE1. Antisense nucleic acid targeted to telomerase RNA and hTERT can inhibit telomerase activity and induce apoptosis of tumor cells [3,4].

Suicide genes TK and CD are powerful in cancer gene therapy. However, their application has been limited due to lack of targeting. Using targeted promoter such as hTERT promoter to regulate suicide gene expression has been a direction in tumor gene therapy. In recent years, we have constructed tumor specific TK expression and enhanced expression vectors using hTERT
promoter and found that transfection of these vectors could specifically kill NPC and its stem cells in vitro and inhibit NPC exograft in null mice in vivo without damaging normal cells and mouse liver and kidney [5-7], indicating that inhibition of telomerase activity is a key step to in NPC treatment.

Study on telomerase inhibitors has become an important area in targeted tumor gene therapy. Pin2/TRF1 interacting protein X1 (PinX1) was recently found as a tumor suppressor and telomerase inhibitor in vivo. It is expressed in normal human tissues, but not or less expressed in tumor tissues. Studies have found that PinX1 can inhibit telomerase activity in gastric and liver tumor cells and induce their apoptosis [8-11]. The expression of PinX1 has been positively correlated with tumor cells and expressed in tumor tissues. Studies have found that PinX1 can inhibit telomerase activity in gastric and liver tumor tissues. Preliminary experiments indicated that PinX1-695 with sense sequence of 5’-GUAAAGAUUGGAAA-GUUATT-3’ and anti-sense sequence of 5’-TTCAUUUCUAACCUUUAU-3’ could effectively downregulate PinX1. Therefore, it was synthesized as FAM-labeled siRNA and used in all experiments.

**Methods**

**Materials**

Austria newborn calf serum, RT-PCR kit and DNA marker were from Takara Biotechnology Co., Ltd. Tetrazolium blue (MTT) was from Sigma. Lipofectamine 2000™ and RNA extraction reagent Trizol were from Invitrogen (USA). Transwell cell culture plates were from Corning (USA). Plasmid extraction kit was from Tiangen Biotech (Beijing) Co. Ltd. Telomerase activity detection kit was from Toyobo Corporation.

**Cell lines**

Human nasopharyngeal carcinoma 5-8 F cells (NPC 5-8 F) and human vascular endothelial cells (VEC) were maintained in RPMI 1640 and DMEM, respectively, supplemented with 10% calf serum, 100 U/mL penicillin and 100 U/mL streptomycin at 37°C in a 5% CO2 incubator as previously reported. After passaged using conventional method, cells were used for experiment at logarithmic phase.

**Plasmid construction**

Synthesized PinX1 DNA was inserted into pEGFP-C3 vector at XhoI and EcoRI sites. Recombinant plasmid was transformed into E. coli DH5α and screened by kanamycin and neomycin resistance. Positive pEGFP-C3-PinX1 was further identified by XhoI and EcoRI digestion and confirmed by DNA sequencing.

**RNA isolation and measurement of PinX1 and hTERT mRNA levels by RT-PCR**

Total RNA was extracted with Trizol 48 h after transfection following the manufacturer’s instruction. Four μL mRNA of each sample was reverse transcribed into cDNA by AMV reverse transcriptase and used as template in RT-PCR. PCR condition used for PinX1 and internal reference GAPDH was 94°C for 2 min followed by 25 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 2 min, and 72°C for 5 min. PCR condition used for hTERT and its internal reference GAPDH was 94°C for 4 min followed by 30 cycles of 94°C for 30 s, 49°C for 30 s and 72°C for 45 s and 72°C for 5 min. The specific primers used in these reactions were followings: PinX1 forward 5’ TTTTCTCGAGATGATCTATGCTGGCT-GAACG 3’ and reverse 5’ TTTTGAAATTCTCATTTTG-GAATTTCTCCTC-3’; hTERT forward 5’ CCGAGTGGACCGTGGCTTTCTCAG 3’ and reverse 5’ GGAAGCAGGTTCGCTGTTTTG-3’ and GAPDH forward 5’ GGAGATGCTGATGGGATT 3’ and reverse 5’ GAGTTGCTGTTGTTTG-3’. The expected PCR products were 987 bp, 670 bp and 205 bp for PinX1, hTERT and GAPDH, respectively. The amplicons were analyzed by electrophoresis, imaged using UV gel.
imaging system and quantified using Quantity one software. Expression levels of PinX1 and hTERT were normalized to internal reference GAPDH.

**Measurement of cell proliferation by MTT**

NPC 5–8 F cells at logarithmic phase were inoculated into 96-well plate with 1 × 10^5 cells in each well. Cell viability at 0 h, 24 h, 48 h and 72 h was examined using MTT method. OD_{490nm} values at each time point were detected in six duplicate wells and their averages were used to plot growth curve and calculate the growth inhibition rate of each treatment using the following formula:

\[
\text{Growth inhibition rate} = \frac{\text{OD}_{490nm \text{ of the control group}} - \text{OD}_{490nm \text{ of the treatment group}}}{\text{OD}_{490nm \text{ of the control group}}} \times 100\%
\]

**Detection of telomerase activity by stretch PCR**

NPC 5–8 F cells at logarithmic phase were inoculated into 6-well plate with 1 × 10^6/well. 24 h later, cells were transfected as described above. 48 h after transfection, telomerase activity was measured using stretch PCR assay based on the protocol provided by the manufacturer. Meanwhile, telomerase activity in control ECV-304 cells was similarly examined.

**Effect of PinX1 on cell migration**

Cell migration was examined using transwell. In detail, NPC 5–8 F cells at logarithmic phase were starved over-night in serum free RPMI 1640 media. Cells were detatched with 0.25% trypsin. After wash with PBS, they were resuspended in RPMI 1640 containing 1 mmol/L CaCl_2, 1 mmol/L MgCl_2, 0.2 mmol/L MnCl_2 and 5 g/L BSA, and adjusted to 1 × 10^5/mL. 200 μL cell suspension was added into the upper chamber of the transwell and 500 μL RPMI 1640 containing 10% newborn calf serum (as a chemokine) was added into the lower chamber of the transwell. The transwell was then cultured at 37°C in a incubator supplemented with 5% CO_2. 24 h later, cells on the upper surface of polycarbonate membrane of the transwell were removed with a cotton swab and the cells that migrated onto the lower surface of the membrane were fixed with 4% paraformaldehyde for 15 min, washed three times with PBS for 5 min each and stained with crystalization violet for 3 min. After further wash with PBS, the membrane was air dried and cell number on the membrane was counted under microscope at 400 magnification. The number of migrated cells was expressed as the average of five randomly selected fields.

**Scratch assay**

Transfected NPC 5-8 F cells at logarithmic phase were inoculated in 6-well plate pre-coated with collagen IV. When monolayer was formed, cells were scratched with a 100 μL tip and cultured in media containing 10% FBS. Zero, 12, 24, and 36 h after scratching, cells in each well were photographed under microscope. The distances between the two edges of the scratched cells in four fields were measured and the average distance was used to calculate the healing rate using the following formula:

\[
\text{Healing rate} = \frac{\text{the distance before healing} - \text{the distance after healing}}{\text{the distance before healing}} \times 100\%
\]

**Measurement of cell cycle and apoptosis by flow cytometry**

48 h after transfection, NPC 5–8 F cells were collected, washed with PBS, resuspended in PBS at 1 × 10^6/mL, and stained with Annexin V and propidium iodide solution (PI) for 15 min at dark. Apoptotic cells were then analyzed by flow cytometry and apoptotic index (AI) was calculated using AI = apoptotic cells/total cells × 100%. Cell cycle was determined after fixing with pre-cooled 75% ethanol at 4°C and wash with PBS.

**Statistical analysis**

Data were expressed as mean ± standard variation and analyzed using SPSS13.0 statistical software package. Differences between samples in RT-PCR, telomerase activity, migration assay, scratch assay, cell cycle and apoptosis assay were tested using single factor analysis of variance and LSD method for multiple comparisons. Differences in between samples in proliferation assay or scratch assay were tested using factorial design analysis of variance and Dunnett’s T3 method for multiple comparisons. A p value less than 0.05 was considered as significant difference. Before comparison, data homogeneity of variance was first examined using F test. In the case of heterogeneity of variance, the approximate variance F test/Welch method was used.

**Results**

We first confirmed the successful construction of PinX1 expression vector pEGFP-C3-PinX1 by digestion with

![Figure 1 The sequencing map of PinX1 gene](image-url)
both XhoI and EcoRI and bi-directional sequence analysis, As shown in Figure 1.

We then examined the transfection efficient under fluorescence microscope. As shown in Figure 2, above 50% of cells were transiently transfected.

We next detected PinX1 mRNA level in transfected cells by RT-PCR. As shown in Figure 3, an expected fragment of 987 bp was amplified in samples isolated from non-transfected NPC 5-8 F cells, lipofectamine treated cells, and cells transfected with pEGFP-C3-PinX1 and pEGFP-C3, respectively, but not in NPC 5-8 F cells transfected with PinX1-FAM-siRNA. Its intensity was the strongest in cells transfected with pEGFP-C3-PinX1. As shown in Table 1, PinX1 mRNA level in cells transfected with pEGFP-C3-PinX1 is 1.6-fold of that in untreated cells \( (p < 0.05) \). By contrast, PinX1 mRNA level in cells transfected with PinX1-FAM-siRNA reduced by 70% compared with that in untreated cells \( (p < 0.05) \). In addition, PinX1 mRNA level in cells treated with lipofectamine alone or transfected with pEGFP-C3 was not significantly changed \( (p > 0.05) \).

Having confirmed that transfection of pEGFP-C3-PinX1 and PinX1-FAM-siRNA could significantly

**Table 1 PinX1 mRNA levels (\( \bar{X} \pm s \))**

| Sample                  | mRNA         | F      | P   |
|-------------------------|--------------|--------|-----|
| pEGFP-C3-PinX1          | 1.601 ± 0.166* | 24.756 | 0.00|
| pEGFP-C3                | 1.223 ± 0.148 |        |     |
| Lipofectamine alone     | 1.042 ± 0.166 |        |     |
| Untreated               | 1.000 ± 0.000 |        |     |
| PinX1-FAM-siRNA         | 0.304 ± 0.055** |       |     |

* vs untreated, \( P < 0.001 \); ** vs untreated, \( P < 0.05 \). PinX1 mRNA level was normalized to GAPDH.
enhance and reduce PinX1 mRNA, respectively, we then explored their effects on NPC 5-8 F cell proliferation using MTT assay. As shown in Table 2, factorial design analysis of variance found that the mean value of OD₄₉₀nm in cells transfected with pEGFP-C3-PinX1 was 2.15, which was significantly decreased compared with that of 2.52 and 2.50 in untreated NPC 5-8 F cells and cells transfected with PinX1-FAM-siRNA, respectively (F = 31.504, *p* = 0.000). In addition, there was no significant difference in the mean value of OD₄₉₀nm in untreated cells, lipofectamine treated cells, cells transfected with pEGFP-C3 and cells transfected with PinX1-FAM-siRNA. Figure 4 shows the cell growth curve by plotting the OD₄₉₀nm value vs time (0 h, 24 h, 48 h and 72 h). Cell growth rate calculated based on the curve indicated that overexpression of PinX1 significantly inhibited the growth of NPC 5-8 F cells, whereas downregulation of PinX1 by siRNA transfection did not affect the growth of NPC 5-8 F cells.

We further explored the effect of PinX1 on NPC 5-8 F cell migration. As shown in Table 3 and Figure 5, overexpression of PinX1 by transfecting pEGFP-C3-PinX1 significantly decreased NPC 5-8 F migration compared with untreated cells (F = 17.162, *p* = 0.000). By contrast, attenuated PinX1 expression by transfection of PinX1-FAM-siRNA did not affect NPC 5-8 F cell migration (*p* > 0.05). In addition, transfection of pEGFP-C3 and treatment with lipofectamine alone did not alter the ability of NPC 5-8 F migration (*p* > 0.05).

We next studied the effects of PinX1 on wound healing ability. As shown in Figure 6, factorial design analysis of variance showed that overexpression of PinX1 by transfection of pEGFP-C3-PinX1 significantly attenuated the mean healing rate of untreated 5-8 F cells from 37.80% to 23.74%, and the healing rates at 12 h, 24 h and 36 h (*p* < 0.001). By contrast, the healing rate of NPC 5-8 F cells was not affected by treatment of lipofectamine alone and transfection of pEGFP-C3 and PinX1-FAM-siRNA (*p* > 0.05).

We then examined the effect of PinX1 on hTERT mRNA level and telomerase activity. As shown in Tables 4 and 5 and Figures 7 and 8, overexpression of PinX1 by transfection of pEGFP-C3-PinX1 significantly

---

**Table 2 OD₄₉₀nm value of NPC 5-8 F cells (X ± s)**

| Sample                  | 0 h   | 24 h  | 48 h  | 72 h  | Total           | Welch/F Value | *P* Value |
|-------------------------|-------|-------|-------|-------|-----------------|---------------|-----------|
| pEGFP-C3-PinX1          | 1.86 ± 0.07 | 2.02 ± 0.11 | 2.23 ± 0.08 | 2.58 ± 0.03 | 2.15 ± 0.27 | 74.246       | 0.000     |
| pEGFP-C3                | 1.85 ± 0.04 | 2.27 ± 0.17 | 2.66 ± 0.15 | 3.07 ± 0.23 | 2.44 ± 0.47 | 57.327       | 0.000     |
| Lipofectamine alone     | 1.87 ± 0.05 | 2.30 ± 0.10 | 2.72 ± 0.13 | 3.12 ± 0.08 | 2.48 ± 0.47 | 156.436      | 0.000     |
| Untreated               | 1.88 ± 0.02 | 2.39 ± 0.23 | 2.78 ± 0.19 | 3.15 ± 0.12 | 2.52 ± 0.50 | 189.690      | 0.000     |
| PinX1-FAM-siRNA         | 1.87 ± 0.01 | 2.35 ± 0.05 | 2.75 ± 0.04 | 3.14 ± 0.12 | 2.50 ± 0.47 | 720.110      | 0.000     |
| Total                   | 1.87 ± 0.04 | 2.27 ± 0.19 | 2.63 ± 0.24 | 3.01 ± 0.25 | 2.42 ± 0.46 | 437.621*     | 0.000     |
| Welch/F value           | 0.309 | 5.696 | 35.155d | 5.600 | 35.870*         | F = 4.592#    |           |
| *P* value               | 0.869 | 0.002 | 0.000  | 0.000  | 0.000           | *P* = 0.000#  |           |

*F and *P* values of major effect; # F and *P* values of interaction effects; Δ: F-test based on heterogeneity of variance. Note: OD value is proportional to the number of live cells and indirectly reflects cell proliferation.
reduced hTERT mRNA level by 21% and decreased telomerase activity in NPC 5-8 F cells (p = 0.000). By contrast, reduced PinX1 by transfection of PinX1-FAM-siRNA had effects on neither hTERT mRNA level nor telomerase activity in NPC 5-8 F cells (p > 0.05). In addition, hTERT mRNA level and telomerase activity in NPC 5-8 F cells were not affected by transfection of pEGFP-C3 and treatment of lipofectamine alone.

We next examined the effect of PinX1 on cell cycle by flow cytometry. As shown in Table 6, overexpression of PinX1 by transfection of pEGFP-C3-PinX1 significantly increased the percentage of NPC 5-8 F cells at G0/G1 phase from 43.0% to 64.0% (p < 0.001). However, downregulation of PinX1 by transfection of PinX1-FAM-siRNA, lipofectamine treatment, and transfection of pEGFP-C3 did not affect the percentage of NC 5-8 F cells at G0/G1 phase.

We last examined the effect of PinX1 on NPC 5-8 F apoptosis by Annexin V/PI staining. Living cells were Annexin V(-)/PI(-) at the lower left quadrant in flow cytometry diagram. Cells with Annexin V(+)/PI(-) at the lower right quadrant were at the early apoptotic status; cells with Annexin V(-)/PI(+) at the upper right quadrant were at late apoptotic status. As shown in Table 7 and Figure 9, overexpression of PinX1 by transfection of pEGFP-C3-PinX1 significantly enhanced AI from 19.266 ± 0.763% in untreated cells and 19.566 ± 0.577% in pEGFP-C3 transfected cells to 49.73 ± 2.668% (p < 0.01). In addition, there was no difference of AI among untreated cells, cells transfected with pEGFP-C3 and cells treated with lipofectamine (p > 0.05).

**Discussions**

Telomerase is a special reverse transcriptase that is composed of RNA and protein and regulates the length of telomere. hTERT is the key component in telomerase and plays important role in genetic stability and maintenance of chromosomes. Studies have found that telomerase is almost not expressed in normal somatic cells, but its expression and activity are enhanced in most immortalized tumor cells [18,19]. Previous studies from our group and others have suggested that telomerase is closely related to the incidence of vast majority of human malignant tumors including nasopharyngeal carcinoma. Enhancement of its activity is the power source of constantly increased proliferation, invasion and metastasis of tumor cells. Therefore, downregulation of telomerase activity in tumor cells is one of the important therapeutic measures to inhibit tumor growth and has become a hot topic in tumor gene therapy. Our study and others have suggested that the targeted TK gene therapy under hTERT promoter or enhanced hTERT/CMV promoter can reduce telomerase activity, eventually leading to the death of tumor cells including NPC [6,7]. Thus, further exploration of specific telomerase inhibitors will be a new direction for future research.

LPTS/PinX1 is recently discovered in cell nucleus as a telomerase inhibitor that binds to Pin2/TRF1 complex in vivo. PinX1 gene is located on chromosome 8p22-23 region, which has high frequency of loss of heterozygosity (LOH) in a series of human cancer cells. LPTS is a novel liver-related putative tumor suppressor gene. The coding sequence of PinX1 is highly homologous to one of the LPTS transcripts, LPTS-L, and considered as a transcript of the same gene [20,21]. Some studies have found that PinX1 can attenuate telomerase activity, inhibit growth of tumor cells and induce apoptosis. Lack of endogenous PinX1 leads to increased telomerase activity and tumorigenicity in nude mice. Therefore, PinX1 is considered as telomerase inhibitor and tumor suppressor. Recent studies have also suggested that PinX1 as tubulin plays an important role in the maintenance of cell mitosis.

The mechanism of PinX1 functioning in tumor cells has not been fully elucidated. Some studies indicate that PinX1 gene can inhibit telomerase activity and induce cell apoptosis, and expression of PinX1 is negatively correlated with hTERT' expression and telomerase activity in tumor cells. For example, Liao et al. [10] reported that upregulation of LPTS-L by transfection of its expression vector in hepatoma cells can inhibit telomerase activity and induce apoptosis; Zhang et al. [22] reported that silencing PinX1 gene using short hairpin RNA can lead to significant shortening of telomere and growth inhibition of telomerase-positive tumor cell, but not telomerase-negative tumor cells, indicating PinX1 affects telomere length and tumorigenicity through regulating telomerase activity; Cai et al. [23] found that reduced PinX1 expression is highly correlated to the poor prognostic factors (such as lymph node metastasis and distant metastasis) in patients with ovarian cancer and considered as an independent factor for poor prognosis of patients with epithelial ovarian cancer; Wang et al. [24] constructed and transfected PinX1 and PinX1-siRNA eukaryotic expression vectors into gastric cancer cells and found that downregulation of PinX1 by
transfection of PinX1-siRNA vector significantly enhanced telomerase activity compared with that of cells transfected with PinX1 vector, suggesting that PinX1 is a telomerase inhibitor and inhibits tumorigenesis and development possibly through telomerase/telomere pathway; Zhou et al. [25] believed that PinX1 inhibits telomerase activity by binding to hTERT through its TID domain, which consequently results in telomere shortening, cell senescence and increase of tumorigenicity in nude mice; Banik et al. [26] analyzed...
the relationship among PinX1, hTERT and hTR, and found that PinX1 can directly bind to hTERT and hTR, but the binding of PinX1 to hTR is dependent on the presence of hTERT. Inhibition of telomerase activity by PinX1 requires its binding to both hTERT and hTR. By contrast, some studies indicate that PinX1 expression is positively correlated to telomerase activity. For examples, Sun et al. [12] found that PinX1 mRNA level is

![Figure 6](http://www.jeccr.com/content/31/1/12)

**Figure 6** Effect of PinX1 on wound healing ability of nasopharyngeal carcinoma 5-8 F cells in scratch assay. Cells transfected with pEGFP-C3-PinX1 (a), pEGFP-C3 (b) and PinX1-FAM-siRNA(e), treated with lipofectamine alone (c), and untreated (d) were inoculated in 6-well plates pre-coated with collagen IV, cultured in media containing 10% newborn calf serum till forming monolayer, then scratched and photographed at 0 h, 12 h, 24 h and 36 h after scratching. The results show that overexpression of PinX1 by transfection of pEGFP-C3-PinX1 significantly increased the wound healing time of NPC 5-8 F cells, while downregulation of PinX1 by transfection of FAM-siRNA reduced has no effect on wound healing.

### Table 4 hTERT mRNA level in each group ($\bar{X} \pm s$)

| Sample            | hTERT mRNA | F     | P     |
|-------------------|-------------|-------|-------|
| pEGFP-C3-PinX1    | 0.789 ± 0.024* | 117.689 | 0.000 |
| pEGFP-C3          | 0.978 ± 0.011 |       |       |
| Lipofectamine alone | 0.987 ± 0.014 |       |       |
| Untreated         | 1.000 ± 0.000 |       |       |
| PinX1-FAM-siRNA   | 1.001 ± 0.085** |       |       |

* vs untreated, $P < 0.001$; ** vs untreated, $P > 0.05$. hTERT mRNA level was normalized to GAPDH.

### Table 5 Telomerase activity in NPC cells ($\bar{X} \pm s$)

| Samples            | Telomerase activity | F     | P     |
|--------------------|---------------------|-------|-------|
| pEGFP-C3-PinX1     | 36227.63 ± 2181.748* | 53.816 | 0.000 |
| pEGFP-C3           | 58346.993 ± 2181.748 |       |       |
| Lipofectamine alone | 59697.199 ± 2181.748 |       |       |
| Untreated          | 62552.354 ± 2181.748 |       |       |
| PinX1-FAM-siRNA    | 63600.608 ± 2181.748** |       |       |

* vs untreated, $P < 0.001$; ** vs untreated, $P > 0.05$. Telomerase activity was normalized to GAPDH.
closely related to hTERT mRNA level in differentiated acute promyelocytic leukemia cells and altered PinX1 expression is secondary response to changes of hTERT expression. In addition, some studies found that PinX1 is not the key factor in inhibition of telomerase activity and its function is rather related to gene polymorphism than to telomerase activity. For example, studies [14] on 159 cases of hereditary prostate cancer identified 39 polymorphisms during PinX1 sequencing; studies [15] on gastrointestinal cancer also found a missense mutation (AGC/TGC) out of 254 codons in 1 case of colon cancer and 1 case of esophageal cancer. The authors suggested that this mutation may be a benign polymorphism because neither de-hypermethylation on its promoter region nor 5-N-2-deoxycytidine treatment of a cell line affected PinX1 expression. In addition, Chang et al. [16] analyzed the function of PinX1 in medulloblastoma and found that 11 polymorphisms in its 7 exons and their splicing sites by direct sequencing and that telomerase activity was not inhibited and related to PinX1, indicating PinX1 did not play a key role in the process of medulloblastoma. Overall, the mechanisms of PinX1 on telomerase/telomere are complicated and may differ in different tumors. Recently, researches on PinX1 dynamics and function have also

Table 6 Percentage of NPC cells in G0/G1 period (X ± s)

| Samples                  | NPC in G0/G1 period (%) | F     | P      |
|--------------------------|-------------------------|-------|--------|
| pEGFP-C3-PinX1           | 64.000 ± 3.905*         | 50.006| 0.000  |
| pEGFP-C3                 | 43.900 ± 2.193          |       |        |
| Lipofectamine alone      | 42.966 ± 1.069          |       |        |
| Untreated                | 43.033 ± 1625           |       |        |
| PinX1-FAM-siRNA          | 42.833 ± 1.484**        |       |        |

* vs untreated, P < 0.001; ** vs untreated, P > 0.05.
advanced our knowledges. Yuan et al. [17] have shown that PinX1 is located in the nucleolus and telomeres in the interphase and gathered around chromosome and outer plate of kinetochore in mitosis phase. Moreover, downregulation of PinX1 by siRNA leads to the aberrant separation of mitotic chromosome, suggesting that PinX1 play an important role in mitotic chromosome separation. Li et al. [27] further found that PinX1 is recruited to the area surrounding chromosome by nucleolin during mitosis to promote chromosomes congression. Chen et al. [28] found that PinX1 binds to Pin2/TRF1 and hTERT at different sites: LPTS/PinX1 (254-289) binds to Pin2/TRF1, while LPTS/PinX1 (290-328) binds to hTERT. Binding of LPTS/PinX1 (290-328) to hTERT in vitro significantly inhibits telomerase activity, leading to telomere shortening and cell apoptosis.

In this study, we successfully constructed PinX1 expression vector pEGFP-C3-PinX1 and found its transfection into NPC cells significantly increased PinX1 mRNA level using RT-PCR, which laid the foundation for study on the roles of PinX1 in NPC cells. Our results also found that overexpression of PinX1 by transfection of pEGFP-C3-PinX1 into NPC cells significantly reduced hTERT mRNA level, telomerase activity, NPC cell growth, migration and wound healing ability, arrested NPC cells in G0/G1 phase and induced cell apoptosis, whereas those phenomena were not found in cells transfected with control vector pEGFP-C3 or treated with lipofectamine alone compared with nontreated NPC cells. These suggest that PinX1 is a potential inhibitor of telomerase activity, in consistence with many other previous reports on tumors.

To better understand the role of PinX1 on tumor cells, we also successfully established PinX1-specific siRNA PinX1-FAM-siRNA, transfection of which significantly silenced 70% of endogenous PinX1 mRNA in NPC cells (p < 0.001). However, PinX1 silencing did not alter telomerase activity, and NPC cell growth and migration. This discrepancy to previous studies [22,24] may be interpreted by the followings: 1) endogenous PinX1 level is already very low in tumor cells, therefore further downregulation has little effect on telomerase activity; 2) silencing PinX1 by transfection of PinX1-FAM-siRNA may be not long enough to observe substantial biological alterations of tumor cells. But no matter how, PinX1-FAM-siRNA may be not long enough to observe substantial biological alterations of tumor cells. But no matter how, PinX1-FAM-siRNA can inhibit PinX1 expression in vitro. Although few studies have been conducted on PinX1 silencing, studies by Zhang et al. [22] and Wang et al. [24] confirmed PinX1 is closely related with telomerase activity.

**Conclusions**

In conclusion, this study systematically analyzed the roles of PinX1 in NPC 5-8 F cells by overexpression or downregulation of PinX1 and found that PinX1 affects NPC cell growth, migration, wound healing ability and cell cycles by inhibiting telomerase activity, suggesting that PinX1 is a potential telomerase inhibitor and has potential therapeutic application in treatment of tumors including NPC. However, the study has some limitations: 1) PinX1 and its siRNA are only transiently transfected, their long-term effects on cells could not be observed; 2) the in vitro experiments may not reflect its role in vivo, therefore further evaluation of the experimental results is needed.

**Acknowledgements**

This work was financially supported by the Guangdong Natural Foundation (91515051501000061).
Author details
1Department of Otolaryngology Head and Neck Surgery, Zhongshan Hospital, Southern Medical University, Guangzhou 510282, China. 2Department of Otolaryngology Head and Neck Surgery, Zhongshan Hospital, Southern Medical University, 253# GongYe Road, Guangzhou 510282, China.

Authors’ contributions
XFL and CSX carried out the subtotal molecular genetic studies, participated in the design of the study, and performed the statistical analysis. ZW conceived of the study, and participated in its design and coordination and drafted the manuscript. YQH carried out the cell culture. CSY participated in the PCR, RT-PCR, telomerase activity and DNA sequence. JQW participated in study work in PinX1 With siRNA. PNZ carried out Transwell cell. HLW carried out the PCR, MTT, telomerase activity and DNA sequence. JQW participated in the design of the study, and performed the statistical analysis. ZW conceived of the study, and participated in its design and coordination and performed the statistical analysis. ZW conceived of the study, and participated in its design and coordination and performed the statistical analysis.

Competing interests
The authors declare that they have no competing interests.

Received: 9 November 2011 Accepted: 8 February 2012 Published: 8 February 2012

References
1. Wen Z, Xiao JY, Tang FQ, Chen BL: The expression of telomerase and telomerase RNA in nasopharyngeal carcinoma (NPC) and HNE, cell lines of NPC. Chin Med J 2000, 113(6):535-538.
2. Wen Z, Xiao JY, Tian YQ, Chen BL: Down-regulation of telomerase and its RNA and apoptosis in HNE1 cell lines of nasopharyngeal carcinoma induced by HTR anti-sense oligo-nucleotide. Int J Mod Cancer Ther 2000, 3(1):77-81.
3. Tian YQ, Wen Z, Xiao JY, Zhao SP, Tang FQ: Apgotosis in HNE1 cell lines of NPC induced by HTR anti-sense oligo-nucleotide. Chinese J Oto-rhino-laryng-skiel Base Surg 1999, 5(4):193-196.
4. He DM, Zhang Y: Inhibition of Leukemic Cell Telomerase Activity by Antisense Phosphorothioate Oligodeoxynucleotides. The Chinese-German J Clin Oncol 2002, 1(2):104-106.
5. Mu SF, Wen Z, Guo MH, Xie MQ, Guan XF, Shen CX: TK gene targeted therapy mediated by the human telomerase promoter for transplanted tumor of nasopharyngeal carcinoma in vivo in nude mouse. Mod J Chinese People’s Liberation Army 2009, 34(2):155-158.
6. Shen CX, Wen Z, Qian YH, Guan XF, Mu SF: Enhanced thymidine kinase gene vector and its killing effect on nasopharyngeal carcinoma in vitro and in vivo. Chinese J Oto-rhino-laryng Head and Neck Surg 2010, 45(3):414-419.
7. Shen CX, Wen Z, Qian YH, Mu SF, Guan XF: Targeted gene therapy of nasopharyngeal carcinoma in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer. J Exp Clin Cancer Res 2010, 13:29-94.
8. Kondo T, Oue N, Marri Y, Kuniyusa H, Noguchi T, Kuraoka K, Nakayama H, Yasu H: Loss of heterozygosity and high-frequency hypomethylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 2005, 24(11):157-164.
9. Ma Y, Wu L, Liu C, Xu L, Li D, Li J: The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population. J Cancer Res Clin 2009, 135(3):431-437.
10. Liao C, Zhao MJ, Zhao J, Ji D, Song H, Li ZP: Over-expression of LPTS-L in hepatocellular carcinoma cell line SMCC7721 induces crisis. World J Gastroenterol 2002, 8(6):1050-1052.
11. Liao C, Zhao M, Song H, Uchida K, Yokoyama KF, Li T: Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 2000, 32(4 Pt 1):721-727.
12. Sun J, Huang H, Zhu Y, Lan J, Li Lai X, Yu J: The expression of telomeric proteins and their probable regulation of telomerase during the differentiation of all-trans-retinoic acid-responsive and–resistant acute promyelocytic leukemia cells. Int J Hematol 2005, 82(3):215-223.
13. Sun J, Tan YM, Huang H, Zhu YY, Lan JP, Lai X: Expression of telomerase inhibitor PinX1 in leukemia cells and its correlation with telomerase activity. Chinese J Pathophysiology 2005, 22(9):1725-1728.
14. Hawkins GA, Chang BL, Zheng SL, Isaacs SD, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Xu J, Isaacs WB: Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 2004, 60(4):298-302.
15. Akiyama Y, Maesawa C, Wada K, Fujisawa K, Itabashi T, Noda Y, Honda T, Sato N, Ishida K, Takagane A, Saito K, Masuda T: Human PinX1, a potent telomerase inhibitor, is not involved in human gastrointestinal tract carcinoma. Oncol Rep 2004, 11(4):871-874.
16. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK: Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 2004, 109(2):309-314.
17. Yuan K, Li N, Jiang K, Zhu TG, Huo YD, Wang C, Li J, Shaw A, Thomas K, Zhang JC, Mann D, Liao J, Jin CJ, Yao XB: PinX1 is a novel microtubule-binding protein essential for accurate chromosome segregation. J Biol Chem 2009, 284(34):23072-23082.
18. Kinglehzu AI: The roles of telomeres and telomerase in cellular immortalization and the development of cancer. Anticancer Res 1999, 19(6A):4823-4830.
19. Wang XW, Xiao JY, Zhao SP, Tian YQ, Wang GP: Expression of telomerase subunits and its relationship with telomerase activity in nasopharyngeal carcinoma. Natt Med J China 2001, 9(12):553-566.
20. Liao C, Zhao MJ, Zhao J, Song H, Pinceau P, Marchio A, Dejean A, Tiollais P, Wang HY, Li TP: Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma. World J Gastroenterol 2003, 9(1):89-93.
21. Park WS, Lee JH, Park JT, Jeong SW, Shin MS, Kim HS, Lee SK, Lee SN, Lee SH, Park CG, Yoo NU, Lee JY: Genetic analysis of the liver putative tumor suppressor (LPTS) gene in hepatocellular carcinoma. Cancer Lett 2002, 178(2):190-207.
22. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang L, Lin J, Sun SP, Yang P, Wang XX, Huang PT, Huang CF, Peng Y, Chen YC, Kung HF, Huang J: Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res 2003, 63(17):75-83.
23. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010, 101(6):1543-1549.
24. Wang HB, Wang WX, Zhou G, Wang WQ, Sun TG, Yang SM, Fang DC: PinX1 inhibits telomerase activity in gastric cancer cells through Mad1/C-Myc pathway. J Gastrointest Surg 2010, 14(8):1227-1234.
25. Zhou XZ, Lu KP: The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001, 107(3):347-359.
26. Bank S, Counter CM: Counter, Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. J Biol Chem 2004, 279(50):51745-51748.
27. Li N, Yuan K, Yan F, Huo Y, Zhu T, Liu X, Guo Z, Yao X: PinX1 is recruited to the mitotic chromosome periphery by Nucleolin and facilitates chromosome congression. Biochem Biophys Res Commun 2009, 384(1):76-81.
28. Chen G, Da L, Xu Y, Xu M, Song L, Li T, Zhao M: C-terminal amino acids 290-328 of LPTS/PinX1 confer telomerase inhibition. Biochem Biophys Res Commun 2010, 398(4):683-689.

Cite this article as: Lai et al.: PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells. Journal of Experimental & Clinical Cancer Research 2012 31:12.

Submit your next manuscript to BioMedCentral and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit